The FDA approved Tizepatide, developed by Eli Lilly and Company, as a weight loss drug (trade name Zepbound™) for obesity (BMI of 30 and above) or overweight (BMI of 27 and above, but with at least one weight-related comorbidities). Adults with high blood pressure, type 2 diabetes, or high cholesterol, for example, lose weight, along with reducing dietary calories and increasing exercise to manage weight. Tizepatide is a dual agonist of glucose-dependent insulin-stimulating polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor developed by Lilly that has a synergistic effect on appetite, calorie intake and metabolic function. With this approval for weight loss, it becomes the first and currently only treatment for weight loss that activates both incretin receptors at the same time.